Form 4: Axogen Director Sells Shares After Option Exercise

Axogen Director William P. Burke exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged trading plan.

Summary

• William P. Burke, a Director at Axogen, Inc. (AXGN), reported transactions involving the exercise of stock options and the sale of common stock.
• On November 10, 2025, Mr. Burke exercised options to acquire 19,227 shares of common stock at an exercise price of $8.14 per share.
• Concurrently on November 10, 2025, he sold 19,227 shares of common stock at a weighted average price of $24.01 per share, with individual sales ranging from $24.00 to $24.10.
• On November 11, 2025, Mr. Burke exercised options to acquire an additional 3,591 shares of common stock at an exercise price of $8.14 per share.
• Also on November 11, 2025, he sold 3,591 shares of common stock at a weighted average price of $24.018 per share, with individual sales ranging from $24.00 to $24.13.
• All sales were conducted pursuant to a Rule 10b5-1(c) trading plan adopted on March 14, 2025.
• Following these transactions, Mr. Burke beneficially owns 100 shares of common stock directly after the first set of transactions and 100 shares directly after the second set of transactions.

Sentiment

Score: 5

Explanation: The filing reports a director's exercise of options and subsequent sale of shares under a pre-arranged plan. While the sale of shares can be seen as a neutral to slightly negative signal, the execution under a 10b5-1 plan mitigates concerns, and the significant profit realized by the director reflects positively on the stock's past performance.

Positives

• The director realized a significant gain by exercising options at $8.14 and selling the shares at weighted average prices of $24.01 and $24.018, indicating a substantial increase in the company's stock value since the options were granted.
• The transactions were executed under a Rule 10b5-1(c) trading plan, which demonstrates pre-planning and can mitigate concerns about opportunistic insider selling.

Negatives

• The director sold all shares acquired through the option exercises, which could be interpreted by some investors as a lack of increased confidence in the company's near-term stock performance, despite the pre-arranged trading plan.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing reports routine insider transactions and does not provide information to assess broader industry trends or competitive positioning for Axogen, Inc.

Stakeholder Impact

• Shareholders: The exercise of options results in minor dilution, and the sale of shares by a director, even under a 10b5-1 plan, can be interpreted as a signal regarding the director's personal view on the stock's valuation, though it's not necessarily indicative of future performance.

Key Dates

Keywords

Axogen, AXGN, Insider Trading, Form 4, Stock Options, Share Sale, Director Transactions, 10b5-1 Plan